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The research work deals with studies on interactions of nanomaterials with components of biosystems, deve-
lopment of new medicines based on magnetite, their application efficiency, chemical engineering of multilevel 
magnetosensitive nanocomposites with a hierarchical architecture and functions of biomedical nanorobots. 
 
INTRODUCTION 
Technology in the twenty first century requires 
the miniaturization of devices into nanometer sizes 
while their ultimate performance is dramatically 
enhanced. This raises many issues regarding to 
new materials for achieving specific functionality 
and selectivity [1]. Nanophase and nanostructured 
materials, a new branch of materials research are 
attracting a great deal of attention because of their 
potential applications in such areas as electronics, 
optics, catalysis, ceramics, magnetic data storage, 
and nanocomposites. The unique properties and 
the improved performances of nanomaterials are 
determined by their sizes, surface structures, and 
interparticle interactions. The role played by 
particle size is comparable, in some cases, to the 
particle chemical composition adding another 
flexible parameter for designing and controlling 
their behavior. Modern nanotechnologies provide 
tools for creation of unique agents for medicine 
and biology. Their practical usage is mostly based 
on the knowledge about interaction of 
nanomaterials with the components of biological 
environment. 
Among the large amount of known materials, 
oxides are of a great interest for scientists. This 
class of compounds possesses a wide variety of 
properties while accumulated knowledge is used 
for their further optimization with respect to cer-
tain applications. This work highlights synthesis 
of highly-dispersive magnetic nanosized oxides 
for various functional purposes and, in particular, 
for cancer therapy. 
Magnetic oxides, magnetite in particular, 
which possess high biocompatibility are of a great 
interest for medico-biological usage [2]. The 
purpose of our work concerns creation of the 
polyfunctional nanocomposite via usage of 
magnetite in a nanosized state as a reactive 
component for targeted design of multilevel 
nanocomposites with hierarchical architecture and 
functions of nanorobots which include recognition 
of specific microbiological objects in biological 
environment, targeted delivery and deposition of 
medicinal products into organs or cells, diagnostics 
and therapy of diseases at the cell level, adsorption 
of cell decomposition products after application of 
chemotherapeutic agents or hyperthermia, their 
removal from the organism using magnetic field. 
The application of polyfunctional nanocomposites 
of combined action, which contain monoclonal 
antibodies and highly efficient cytostatic compo-
unds, in oncology may be accompanied by a syner-
getic effect of chemo- and immunotherapeutic 
drugs and result in decreased toxico-allergic 
response of the organism. 
For any practical application, the 
fabrication of nanoparticles needs to be 
controlled in such a way that resulting 
nanoparticles have the following characteristics: 
(i) identical size of all particles, (ii) identical 
shape or morphology, (iii) identical chemical 
composition and crystal structure desired among 
different particles and within individual particles, 
such as core and surface composition must be the 
same, and (iv) individually dispersed or 
monodispersed, i.e. no agglomeration. If 
agglomeration does occur, nanoparticles should 
be readily redispersible [3–5]. 
In view of the increasing interest in magnetic 
nanoparticles in the field of medical care as 
described above, a facile synthetic process which 
allows to control the size, magnetic properties, 
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and surface properties of Fe3O4 nanoparticles, 
needs to be developed because those properties 
required for the Fe3O4 nanoparticles depend on 
the specific application. For example, the size of 
Fe3O4 nanoparticles needs to be controlled for 
target materials such as proteins, genes, and cells 
whose sizes are 5–50 nm, 2 nm wide and 10–
100 nm long, and 10–100 µm, respectively. 
Furthermore, it is possible that particle size plays 
an important role in determining the state of 
aggregation of the nanoparticles and even the 
uptake property to living organisms. Additionally, 
magnetic nanoparticles synthesized by the facile 
method are expected to have surface properties 
which are easy to be characterized or modified 
with biomolecules for biomedical applications [6].  
Magnetic nanoparticles are attractive for their 
unique properties, such as single domain structure 
and superparamagnetism, which are not observed 
for bulk materials, and are expected to be 
applicable in various fields including ultrahigh-
density magnetic recording media, drug delivery 
systems, and medical imaging. Important for 
these applications are the techniques for 
stabilizing the nanoparticles in the solvent and 
those for functionalizing the nanoparticles surface 
by surface modifications. Especially for the 
bioapplications of magnetic nanoparticles, the 
surface modification with organic molecules or 
surfactants is essential for inhibiting the 
aggregation of nanoparticles and for controlling 
interparticle interactions and solubility in an 
aqueous solution. In addition, surface 
modification by biologically relevant substances 
improves the biocompatibility which enables the 
bioapplications of magnetic nanoparticles. Thus, 
surface modification of magnetic nanoparticles has 
become one of the most challenging issues recently.  
The cell-based therapy is one of advanced 
treatments applied to various fields of scientific 
study, and it includes immunotherapy, gene 
therapy, and regenerative medical treatment. 
Recently, immunotherapy has been vigorously 
investigated in the field of oncology because of 
specific anti-tumor activity and less side-effect. 
Cancer treatment by immunotherapy takes 
advantage of having efficient effector cells which 
exhibit specific killing activity against cancer 
cells. However, local accumulation inside the 
tumor of these effector cells remains one of 
critical issues to be overcome from a point of the 
clinical view. Therefore, drug delivery system is a 
good candidate to achieve the efficient 
localization of drugs in the tumor. Actually, 
successful local delivery of drugs is reported 
using magnetic nanoparticles such as magnetite 
(Fe3O4) or maghemite (γ-Fe2O3) as a nanocarrier 
[7]. Thus, the application of magnetic drug 
delivery system to immunotherapy could make 
the development of magnetically mediated 
immunotherapy possible in the clinical field.  
SYNTHESIS AND PROPERTIES OF 
MAGNETITE 
Highly disperse magnetite was prepared via 
co-precipitation of salts [7, 8] in accord to the 
reaction 
Fe+2+2Fe+3+8NH4OH → 
→ Fe3O4+4H2O+8NH4+.           (1) 
Fractionation of the prepared magnetite was 
carried out with magnetic field.  
The method [7, 8] permits obtaining 
magnetite with broad size distribution of the 
particles (from microns to nanometres) which 
requires additional fractionation. 
In order to achieve a better control over size 
distribution, we developed a cryochemical 
method of heterogeneous synthesis of magnetite 
at interface of solid (frozen iron II and III salts 
solution) and liquid (ammonia solution of a 
certain concentration) phases [3]. The ammonia 
solution is taken in excess while the second phase 
melts and releases the solution which has 
predetermined concentrations of the reactive 
components. A permanent concentration gradient 
is maintained at the thin interface upon melting 
the iron-containing solid. On the contrary to the 
homogeneous synthesis, growth of the 
nanoparticles is terminated at a certain distance 
from the solid phase due to absence of the iron 
salts. This prevents the further growth of the 
formed nanoparticles and preserves their initial 
size. The nanoparticles are collected with non-
uniform magnetic field and the supernatant 
solution is removed. The precipitate is washed 
many times with water in order to dispose off the 
anions present in the solution. 
Samples of the nanocrystalline magnetite 
with specific surface area of ~ 90–180 m2/g 
(measured by thermal desorption of Ar) were 
prepared using the cryochemical method. 
Depending on the synthetic conditions, the 
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particles size comprised 6–50 nm revealing a 
quite narrow distribution interval. The fraction of 
the mostly monodomain magnetite particles of 
20–50 nm in diameter was used for preparation of 
the magnetic carriers. 
The advantages of the proposed method 
comprise the increased yield of the monodomain 
magnetite particles directly from the synthesis 
and their narrower size distribution. 
COATING OF MAGNETITE SURFACE WITH 
POLYACRYLAMIDE 
Stabilization and biocompatibilization of the 
nanosized magnetite particles were achieved via 
coating their surface with cross-linked poly-
acrylamide (PAA). The PAA layer was prepared 
via co-polymerization of acryl amide and N,N’-
methylene-bis-acryl amide in high-frequency 
(HF) discharge plasma at the radiator power 
20 W [9–11]. The monomer and the cross-linker 
were coated onto the magnetite surface in a rotor 
evaporator at 303 K. Plasma polymerization was 
carried out in glowing discharge at 1⋅10-3 Pa. 
Conversion degree of carbon-carbon double bonds 
was measured by the method of Kaufmann based on 
titration in a non-aqueous solution and the ability of 
the С=С bonds to combine with Br2 [12]. The 
obtained samples were studied in the wavelength 
range 400–4000 см-1 with a FTIR "Perkin Elmer" 
spectrometer (the model 1720Х) [13–15]. The 
spectra revealed absorption bands related to the 
initial magnetite and the PAA coating [16]. 
We studied magnetic properties of the 
magnetite particles modified with PAA and the 
impact of the coating thickness. The coating 
weight was varied from 5 to 50% of the total 
weight of the composite. The specific 
magnetization σі and its function σі = f(Н) were 
calculated from the experimental data. From 
them, the ultimate magnetization at saturation 
condition σs, the remnant magnetization σr, and 
the coercive force Нс were determined [17]. 
The experimental functions of the specific 
magnetization on magnetic field strength for the 
bare magnetite and the magnetite with various 
PAA coating contents showed that the coating 
fraction up to 15 wt. % does not cause notable 
deviations from the initial magnetite magnetic 
properties. The values σs, Нс are located in the 
ranges from 61.5 10-7 to 62.0·10-7 Т·m3/kg and 
from 7.20 to 3.44 kА/m, respectively, while σr is 
equal to 15.12·10-7 Т·m3/kg. Increase in the coating 
weight up to 50% leads to the lower σs, Нс, σr 
values: down to 51.1·10-7 Т·m3/kg, 6.31 kА/m, and 
10.74·10-7 Т·m3/kg, respectively. These results 
show that the increase in the weight fraction of the 
PAA layer up to 50% makes a negligible 
contribution to the specific magnetic properties. 
MODIFICATION OF MAGNETITE WITH 
γ -AMINOPROPYLSILOXANE 
Surface of magnetite nanoparticles was 
coated with γ-aminopropylsiloxane (γ-APS) in 
toluene [18]. The reaction of polycondensation 
was carried out in accord to the scheme 
–OH+(C2H5O)3Si(CH2)3NH2 →  
→ –O–Si(CH2)3NH2+3C2H5OH .          (2) 
γ-Aminopropyltriethoxysilane (γ-APTES) 
was dried over molecular sieves and purified with 
distillation in vacuum. Magnetite was exposed to 
a solution of γ-APTES (10% vol.) in toluene for 
8 h, precipitated in a centrifuge, washed with 
toluene, acetone, and dried at 293 K. 
The content of functional groups on the 
surface of magnetite was found with X-ray 
Photoelectron Spectroscopy (XPS) and Differen-
tial Scanning Calorimetry (DSC) combined with 
Differential Thermo-gravimetric Analysis (DTA). 
The thermal graphs were recorded in the tempe-
rature range 293–1273 К at the heating rate 
0.16 deg/s on a Q-1500D thermal analyzer 
purchased from the company MOM (Hungary). 
Concentration of the –OH groups at the surface of 
the magnetite nanoparticles calculated from the 
DTA data was equal to 2.2 mmol/g or 
2.4 µmol/m2 at Sspecific = 90 m2/g [19]. 
Presence of the amino-groups at the surface 
of the obtained nanocomposite was confirmed 
with XPS [20]. The XPS spectra were recorded 
on a spectrometer EC-2402 with an analyzer 
"PHOIBOS-100" SPECS using the Кα radiation 
of a Mg anode (EMgKα = 1253.6 eV). The 
spectrometer was calibrated using the line Au 
4f7/2 which has the binding energy Eb = 84 eV. 
Fourier Transfrom Infrared spectra were 
recorded on a spectrometer "Perkin Elmer" (the 
model 1720X) in the range 400–4000 cm-1. 
Pronounced absorption bands at 1037 and 1130 
cm-1 of approximately equal intensities indicates 
formation of a polymer layer Si–О–Si at the 
magnetite surface resulted from hydrolytic 
polycondensation of the modifier molecules [19].  
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SURFACE-IMMOBILIZATION OF HUMAN 
IMMUNOGLOBULIN  
We developed procedures for 
immobilization of antibodies at surfaces of the 
magnetite-based nanocomposites coated with 
polyacrylamide (PАА) [16] and polysiloxane 
(γ-АPS) [19] using a model preparation of 
human normal immunoglobulin (Ig) produced by 
Biofarma, Kyiv. The Ig was purified via dialysis 
in order to remove low molecular weight 
preserving compounds. 
We measured isotherms of physical adsorption 
of Ig to the surfaces of the nanocomposites. 
Samples of the nanocomposites (100 mg) were 
introduced into Ig solutions (5 ml) of varying 
concentration. Adsorption of Ig was carried out in 
physiological conditions during 2 h upon shaking 
at ambient temperature. The amount adsorbed at 
the surfaces of the nanocomposites was 
determined from the difference between the Ig 
concentrations before and after adsorption. The 
concentrations were measured on a Lambda 
35 uv/vis Spectrometer supplied by Perkin Elmer 
Instruments at the wavelength λ = 280 nm using a 
calibration curve. The results are presented in 
Tables 1, 2 and Fig. 1 a, b. 
Table 1. Isotherm of non-specific adsorption of human 
normal immunoglobulin to the nanocompo-
site Fe3O4/ PАА 
С0, mg/ml D(280 nm) Сeq., mg/ml Аphys., mg/g 
0.35 0.485 0.33 0.84 
0.45 0.629 0.43 0.90 
0.55 0.776 0.53 0.85 
0.71 0.966 0.66 2.32 
0.86 1.153 0.79 3.40 
1.40 1.762 1.21 9.48 
 
Table 2. Isotherm of non-specific adsorption of human 
normal immunoglobulin to the nanocomposite 
Fe3O4/ γ-АPS 
С0, mg/ml D(280 nm) Сeq., mg/ml Аphys, mg/g 
0.15 0.249 0.18 0.00 
0.25 0.305 0.22 0.00 
0.45 0.607 0.44 0.64 
0.55 0.745 0.54 0.66 
0.71 0.964 0.69 0.80 
0.86 1.178 0.85 0.57 
1.00 1.361 0.98 0.97 
1.40 1.911 1.38 1.18 
We recorded isotherms of covalent binding of 
Ig to the surfaces of the nanocomposites. The 
chosen mechanism of the covalent binding 
comprises reaction of aldehyde groups created 
upon periodate oxidation of Ig side carbohydrate 
chains with amino-groups located at the grafting 
surfaces leading to formation of Schiff-bases 
(imines). An advantage of this mechanism is 
oriented immobilization of the antibody molecules 
with the Fc fragment (fragment crystallisable) 
facing the surface and the Fab fragment (fragment 
antigen binding) sticking out [21, 22]. 
 
 
a 
 
b 
Fig. 1. Comparison of isotherms of physical adsorption of 
human normal Ig (1) and the covalent binding of 
the oxidized human Ig (2) to the nanocomposites: 
а – Fe3O4/PАА; b – Fe3O4/γ-АPS 
 
The nanocomposites consisting of magnetite 
nanoparticles coated with PAA were activated by 
ethylenediamine (ED) in order to form amino-
groups at the surface in accord to the reaction 
scheme [23] 
–PAA–CO–NH2+H2N–(CH2)2–NH2 → 
│–PAA–CO–NH–(CH2)2–NH2.    (3) 
Since the surface of the nanocomposite 
Fe3O4 / γ-АPS contains native amino-groups, no 
additional treatment was carried out. 
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Oxidation of human normal immunoglobulin 
was carried out in 0.1 M NaIO4 solution prepared 
on the basis of aqueous 0.02 M acetate buffer 
(pH 5.0) in accord to the reaction scheme 
Ig–gly + NaIO4 →Ig–COH + NaIO3.         (4) 
The oxidized Ig was purified with dialysis 
against 2 l of 0.02 M acetate buffer (pH 5.0). The 
solution obtained after the dialysis was set to 
pH 8–9 with 0.06 M carbonate-hydrocarbonate 
buffer based on 0.15 M NaCl (pH 9.5). 
Covalent binding of Ig to the nanocomposites 
Fe3O4/PАА activated by ED and Fe3O4/γ-APS 
(30 mg) was carried out from 7 ml solution of 
0.06 M carbonate-hydrocarbonate buffer (pH 9.0) 
and 0.15 M NaCl during 2 h at the ambient 
temperature upon shaking in accord to the 
reaction scheme 
carrier–R–NH2–Ig →  
→ carrier–R–N=CH–Ig+H2OSchiffbase.   (5) 
The bound Ig amount was determined from 
the difference between the initial and the final 
concentrations of the contact solution. The 
concentrations were measured by UV absorption 
at λ = 280 nm using a calibration curve. The data 
on isotherms of the covalent binding are shown in 
Tables 3, 4 and Fig. 1 a, b. 
Table 3. Isotherm of the covalent binding of oxidized 
human normal immunoglobulin to the 
nanocomposite Fe3O4/PАА 
С0, mg/ml D(280 nm) Сeq., mg/ml А(Ig/PАА), mg/g 
0.15 0.201 0.128 5.07 
0.25 0.288 0.184 15.52 
0.35 0.420 0.268 19.14 
0.45 0.528 0.337 26.48 
0.55 0.630 0.402 34.59 
0.71 0.841 0.536 40.57 
0.86 0.974 0.621 55.79 
1.00 1.144 0.730 63.04 
1.40 1.416 0.903 116.00 
 
The obtained isotherms of non-specific 
adsorption (Tables 1, 2) and the covalent binding 
(Tables 3, 4) of Ig to the nanocomposites are 
linear functions with no saturation in the studied 
concentration range (Fig. 1 a, b). The experi-
mental data were converted to the analytical form 
using the equation y = E·x, and the respective 
distribution coefficients E (ml/g) were calculated. 
The coefficients reflect the Ig distribution 
between the nanocomposites surfaces and the 
contacting solutions. The coefficients (E) and the 
Ig amounts immobilized at the nanocomposites’ 
surfaces at the concentration of the Ig initial 
solution 1.4 mg/ml (the maximal in the 
experiment) are summarized in Table 5. The 
coefficients for the covalent binding exceed the 
respective coefficients for non-specific adsorption 
by more than an order and reflect equilibrium 
shift towards surface immobilization of Ig. 
 
Table 4. Isotherm of covalent binding of oxidized 
human normal immunoglobulin to the 
nanocomposite Fe3O4/ γ-АPS 
С0, mg/ml D(280 nm) Сeq., mg/ml А(Ig/PАА), mg/g 
0.15 0.282 0.140 2.42 
0.25 0.352 0.224 6.14 
0.35 0.468 0.298 12.07 
0.45 0.594 0.379 16.67 
0.55 0.723 0.461 20.70 
0.71 0.924 0.590 28.08 
0.86 1.025 0.653 48.19 
1.00 1.207 0.770 53.71 
1.40 1.742 1.111 67.41 
 
Table 5. Values of human Ig adsorption to the nano-
composites surfaces of different nature at the 
concentration of the initial Ig solution 
С = 1.4 mg/ml 
Nanocomposite Аphys., 
mg/g 
Еphys., 
ml/g 
Аcov.,  
ml/g 
Еcov., 
ml/g 
Fe3O4/PАА 9.48 6.1 116.00 83.53 
Fe3O4/γ-АPS 1.18 0.92 67.41 59.51 
 
It should be noted that a significant part of Ig 
(64–80%) remains in the solution upon covalent 
binding since the reaction of Schiff base 
formation is reversible (Tables 3, 4). 
The nature of nanocomposite surface 
influences the values of both the physical and the 
covalent immobilization of Ig. The amounts of 
immobilized Ig and the distribution coefficients 
are higher for the nanocomposite Fe3O4/PAA. 
We studied kinetics of release of Ig to model 
environment (0.15 M NaCl) for the 
nanocomposites Fe3O4/PАА and Fe3O4/γ-АPS 
which carried physically and covalently bound Ig 
and had been prepared upon measurements of the 
respective isotherms. The samples of the 
nanocomposites (0.030 g) carrying physically or 
covalently bound Ig were placed into 5 or 7 ml of 
0.15 M NaCl, respectively, and the UV 
absorption at 280 nm of the solution was 
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measured after gentle shaking for certain time 
intervals. The concentration of the desorbed Ig 
was calculated using the calibration curves. 
Physically immobilized Ig desorbed during 
1–2 min, the desorption curves are not shown. 
The data on desorption of covalently bound Ig are 
summarized in Tables 6, 7 and Fig. 2 a, b. 
Parameters of the release kinetic curves were 
calculated by the method of least squares using 
the equation y(х)=y0+Ae-x/t, where y0 is the 
amount of bound Ig which is not released at the 
given conditions, A is the amount of bound Ig 
which is being released, 1/t characterizes release 
dynamics and curvature of the kinetic function. 
 
 
a 
 
b 
Fig. 2. Kinetics of release of covalently bound human 
immunoglobulin from the surface of the 
nanocomposites а – Fe3O4/PАА, b – Fe3O4/γ-
APS. The initial bound amounts of 
immunoglobulin are shown in the right panels. 
The curves y=y(0)+Ae-x/t were calculated from the 
experimental data by the method of least squares 
 
Table 6. Parameters of the equation y=y(0)+ Ae-x/t 
describing release kinetics of covalently 
bound human immunoglobulin from the 
nanocomposite Fe3O4/PАА 
 у(0)=55.8 
mg/g 
у(0)=40.6 
mg/g 
у(0)=34.6 
mg/g 
у(0)=19.1 
mg/g 
у(0)=15.6 
mg/g 
у0 49.77±3.25 30.40±41.22 25.94±0 11.09±0 0±0 
А 2.76±5.62 11.35±0 8.65±0 8.05±0 15.52±0 
t 0.27±1.45 1.80±19.54 2.64±1.24 4.37±1.35 6.51±2.45 
 
Table 7. Parameters of the equation y=y(0)+Ae-x/t 
describing release kinetic of covalently 
bound human immunoglobulin from the 
nanocomposite Fe3O4/γ-APS 
 у(0)=48.2 mg/g у(0)=28.1 mg/g у(0)=12.1 mg/g 
у0 28.69±3.89 9.13±0 0±0 
А 17.60±4.89 18.93±3.11 12.06±3.97 
t 60.15±55.12 14.93±8.03 12.18±17.68 
 
The obtained kinetic data show that the 
released Ig amount decreases upon increase of the 
amount initially immobilized at the surfaces of 
both nanocomposites. For small amounts of 
immobilized Ig 15.5 mg/g (Fe3O4/PAA) and 
12.0 mg/g (Fe3O4/γ-APS), up to 30% of the Ig is 
released during the first 5–10 min. For higher 
immobilized Ig amounts 55.8 mg/g (Fe3O4/PAA) 
and 48.2 mg/g (Fe3O4/γ-APS), 16–18% of the Ig 
is released during the first 10–15 min. Release of 
surface-immobilized Ig bound via Schiff bases 
occurs slower and at lower extent than of 
physically bound Ig. 
IMMOBILIZATION OF THE CD 95 
ANTIBODY 
We prepared nanocomposites carrying anti-
tumour drug cisplatin and monoclonal mouse 
antibody CD 95 against the human Fas-antigen of 
the isotype IgG1, kappa, the clone DX2 produced 
by DakoCytomation (Denmark). The 
concentration of the initial solution of the 
antibody was 20 µg/ml. 
We studied both non-specific (physical) 
adsorption and the covalent binding of the 
monoclonal antibody CD 95 to the 
nanocomposites Fe3O4/PAA and Fe3O4/γ-APS. 
We prepared 4 samples (0.03 g). Each sample 
was introduced into 1.0 ml solution of the 
antibody or 1.7 ml solution of the oxidized 
antibody, respectively: 
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1. Fe3O4 / PАА + СD 95; 
2. Fe3O4 / γ-APS + СD 95; 
3. Fe3O4 / PАА + СD 95oxidized; 
4. Fe3O4 / γ-APS + СD 95oxidized. 
 
Physical adsorption of the monoclonal 
antibody CD 95 (20 µg/ml) to the 
nanocomposites (the samples 1 and 2) was carried 
out in 0.15 M NaCl (1.0 ml) during 2 h upon 
shaking at the ambient temperature. 
Oxidation of the monoclonal antibody CD 95 
was carried out in acetate buffer-based solution of 
0.1 M NaIO4 (pH 5.0). The oxidized CD 95 was 
purified by dialysis against 2 l of 0.02 M acetate 
buffer (pH 5.0). The solution of the oxidized 
antibody was set to pH 8–9 after dialysis against a 
solution of 0.06 M carbonate-hydrocarbonate 
buffer (pH 9.5) and 0.15 M NaCl. The 
concentration of the antibody CD 95 after the 
dialysis was equal to 13 µg/ml. 
Covalent bonding of the oxidized and 
purified monoclonal antibody to the 
nanocomposites Fe3O4/PАА (activated with ED) 
and Fe3O4/γ-APS (the samples 3 and 4) was 
carried out in a solution of 0.06 M carbonate-
hydrocarbonate buffer (pH 9.0) and 0.15 M 
NaCl during 2 h upon shaking at the ambient 
temperature. Then the nanocomposites were 
separated using magnetic field and the antibody 
concentrations in the contact solution were 
measured using a combined reader for a 
microplate Synergy HT, Model SIAFRTD, 
Serial Number 202993 (Bio Tek). 
Quantitative measurements of protein 
contents in the solutions were carried out by the 
method of Bradford [24]. The method is based on 
recording light absorption of a complex between 
Coomassie Blue G-250 dye and protein which has 
a maximum at 595 nm. The antibody 
concentration was determined from a calibration 
curve. The adsorbed amount of the antibody was 
calculated from the difference between its 
concentrations in the contact solution prior and 
after adsorption (Table 8). 
The obtained results show that the covalent 
binding via Schiff bases has the following 
advantages with respect to non-specific 
adsorption: higher thermodynamic stability of the 
immobilized layer originating from the covalent 
bonding and better kinetic stability due to 
hampered release arising from slow hydrolysis of 
the Schiff bases. 
Table 8. Immobilization of the monoclonal antibody 
CD 95 at the surfaces of magnetosensitive 
nanocomposites Fe3O4/PАА and Fe3O4/γ-APS  
Nanocomposite С0, 
 µg/ml 
D Сeq., 
µg/ml 
А(СD 95), 
µg/g 
Fe3O4/PАА 
+ СD 95 
20.00 0.44 19.93  2.3  
Fe3O4/γ-APS 
+ СD 95 
20.00 0.42 19.96  1.2  
Fe3O4/PАА 
+ СD 95oxidized 
3.88 0.73 1.00  163.2 
Fe3O4/γ-APS 
+ СD 95oxidized 
3.88 0.72 1.45 137.7 
where С0    is the initial antibody concentration; 
 D    is the optical density; 
 Сeq,is the equilibrium concentration of the 
antibody upon adsorption; 
 А    is adsorbed amount of СD 95 at the sur-
faces of the nanocomposites 
IMMOBILIZATION OF CISPLATIN AT THE 
SURFACES OF THE NANOCOMPOSITES 
Cisplatin (CP) is an anti-tumour platinum-
containing drug supplied as aqueous solution. 
Mechanism of the anti-tumour activity of platinum 
derivatives comprises DNA chains bifunctional 
alkylating which suppresses biosynthesis of 
nucleic acids and induces cells’ apoptosis. 
CP passes poorly through the hematoencephalic 
barrier and is quickly transformed into inactive 
metabolites. Binding to proteins in the state of the 
metabolites reaches 90%. 
The period τ1/2 of half-excretion of the drug 
from blood is equal to 20–49 min at the initial 
stage, 58–73 h at the final stage assuming normal 
excretion kidney function, and 240 h upon anuria. 
The drug is excreted by kidneys in the amount of 
27–43% in 5 days while platinum can still be 
found in tissues during 4 months after introduction.  
We studied stability of CP via measuring its 
cytotoxic activity after 10, 20, and 30 days and 
found that it remains constant within a month. 
Adsorption kinetics of CP at surfaces of the 
nanocomposites [25] was measured upon shaking 
an aqueous solution of CP (50 ml) with magnetic 
particles of the nanocomposites (200 mg) during 
18 h at the ambient temperature. Probes (5 ml) 
were taken from the solutions every 2 h. The 
adsorbed amounts were determined as the 
difference between the initial and current 
concentrations of Pt2+ ions in the contact 
solutions. The measurements were carried out 
with a single beam two-channel atomic-
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absorbance spectrophotometer C-115 M1 with 
flame atomizer, deuterium background corrector, 
and digital registration. A hollow cathode lamp 
for platinum (the analytical line 265.9 nm) and 
the fuel-oxidizer system acetylene-air were used. 
The adsorption kinetic curves are shown in 
Fig. 3 a, b. 
 
a 
 
b 
Fig. 3. Kinetic curves of adsorption of cisplatin at the 
surfaces of the magnetosensitive nanocomposites 
Fe3O4/PАА (a) and Fe3O4/γ-АPS (b) 
 
The adsorbed amounts of cisplatin (calculated 
for Pt2+) at the surfaces of the nanocomposites 
Fe3O4/PАА and Fe3O4/γ-АPS comprise 128 mg/g 
and 98.3 mg/g, respectively. The major part of the 
drug is adsorbed during the first 2–3 hours. 
PREPARATION AND CYTOTOXIC 
PROPERTIES OF MAGNETICALLY DRIVEN 
POLYFUNCTIONAL NANOCOMPOSITES 
(MODELS OF NANOROBOTS) 
We prepared the following samples for 
studies of impact of the magnetically driven 
nanocomposites carrying the cytostatic drug and 
the monoclonal antibody on vital activity of 
cancer cells: 
1. Fe3O4 / PАА + CD 95; 
2. Fe3O4 / PАА + CP; 
3. Fe3O4 / PАА + CD 95 + CP; 
4. Fe3O4 / γ-АPS + CD 95; 
5. Fe3O4 / γ-АPS + CP; 
6. Fe3O4 / γ-АPS + CD 95 + CP. 
The antibody CD 95 was bound to the 
nanocomposites via formation of Schiff bases 
(the samples 1, 3, 4, 6). The samples 3 and 6 were 
prepared in two steps: firstly, the oxidized 
monoclonal antibody CD 95 was conjugated with 
the nanocomposites Fe3O4/PАА (activated with 
ED) and Fe3O4/γ-АPS, then the cytostatic drug 
was adsorbed. 
Oxidation of the monoclonal antibody CD 95 
was carried out in accord to the reaction scheme (4). 
Covalent binding of the monoclonal antibody 
CD 95 (V = 1.7 ml, C = 3.88 µg/ml) to the 
surfaces of the nanocomposites Fe3O4/PАА 
(activated with ED) and Fe3O4/γ-АPS was carried 
out during 1.5 hours upon shaking at the ambient 
temperature in accord to the reaction scheme (5). 
The obtained magnetic samples were collected in 
magnetic field of a permanent magnet. 
The nanocomposites containing the 
covalently bound monoclonal antibody (the 
immobilized amounts of CD 95 were 163.2 mg/g 
for Fe3O4/PАА and 137.7 mg/g for Fe3O4/γ-АPS) 
were introduced into 10 ml of CP aqueous 
solution (1 mg/ml). Adsorption was carried out 
for 4 hours upon shaking. The precipitate was 
collected in magnetic field of a permanent 
magnet. The adsorbed amounts of CP were 
128 mg/g for Fe3O4/PАА and 98.3 mg/g for 
Fe3O4/γ-АPS. 
Cytotoxic impact of the nanocomposites 
carrying immobilized the monoclonal antibody 
and the cytostatic drug on cancer cells was 
studied in vitro. The nanocomposites were taken 
in the amounts which contained the quantity of 
CP equal to the biological equivalent of 
efficiency IC25, i.e. 25% of the IC concentration 
which 100% suppresses the cells. Our earlier 
experiments showed that IC50 = 5 µg/ml, 
therefore IC25 = 2.5 µg/ml. At that concentration 
of the nanocomposites, the concentration of the 
monoclonal antibody CD 95 was equal to 
0.2 µg/ml (the doze used for clinical treatment is 
equal to 10–30 µg/ml). The studies of 
cytotoxicity were carried out at P.E. Kavetsky 
Institute of Experimental Pathology, Oncology, 
and Radiobiology of the National Academy of 
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Sciences of Ukraine [26]. The cytotoxic impact of 
the nanocomposites Fe3O4/PАА and Fe3O4/γ-АPS 
carrying immobilized the monoclonal antibody 
CD 95 and CP was measured for the human 
mammary gland cancer cell line MCF-7. The 
cytotoxic activity of the respective 
nanocomposites carrying only CP or only the 
monoclonal antibody was also measured for 
comparison. The following solutions were used as 
the control samples: pure nutrient medium, CP 
(2.5 µg/ml), and the monoclonal antibody CD 95 
solution (0.2 µg/ml). We studied also the 
cytotoxic effect of the bare magnetite 
nanoparticles and the bare nanocomposites 
Fe3O4/PАА and Fe3O4/γ-АPS. 
The volumes 100 µl of the MCF-7 line cells 
(1·105 cells/ml) were deposited into 96-cavity 
microplates. The cells were cultivated in a 
modified medium Dulbecco – ISCOV (Sigma, 
Germany) with addition of 10% embryonic calve 
serum and antibiotic gentamycin at 40 µg/ml in 
standard conditions at 37оС and air saturation 
with 5% CO2. The samples being studied were 
added to the cells after a 24 hour period of the 
cells adapting to the cultivating conditions. Each 
sample was added in 3 parallels and incubated in 
the same conditions. Cytotoxicity was measured 
after 24 hours.  
The impact was evaluated with the MTT-
colorimetric test, The method is based on the 
ability of mitochondrion ferments of living cells 
to convert 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (yellow salt) 
into crystalline MTT-formazan (lilac) [26]. The 
MTT solution (Sigma, 20 µl, 5 mg/ml in 
phosphate-saline buffer) was added to the cavities 
of the plastic plate and incubated for 3 hours. 
Then the plate was centrifuged at 1500 rev/min 
for 5 min and the supernatant was removed with 
an automated suction. Dimethylsulfoxide (Serva, 
100 µl) was added to each cavity to dissolve the 
formazan crystals. The optical absorbance was 
measured with a multi-cavity spectrophotometer 
at the wavelength 540 nm. The results of the 
study are summarized in the Table 9.  
In accord to the obtained data, the 
magnetosensitive nanocomposites carrying 
adsorbed CP in quantity twice below the 
therapeutic range and the amount of the 
monoclonal antibody CD 95 almost by one order 
lower cause death of 46–57% of the tumour cells 
which exceeds the impact of the control solution 
(CP+CD 95) by up to 50%. This synergy effect 
can be explained as follows. Firstly, the targeted 
delivery of the complex cytostatic drug–
antibody to the tumour cells was accomplished. 
The cytotoxic effect of CP is achieved through 
formation of covalent bonds between the drug 
and DNA. Traumatic effect of the 
nanocomposite on the cell membrane facilitates 
the process and improves transport of the 
therapeutic preparation through the membrane 
barrier. Bifuctional products of the interaction, 
the so-called DNA-adducts, block replication, 
transcription, and, as a consequence, cell 
proliferation. Secondly, the system 
ligand/receptor plays an important role in 
apoptosis of malignant cells. The antibody 
binding its receptor launches a system of signal 
transmission which leads to apoptosis. There are 
also reports [6] that this system may cause death 
of tumour cells upon influence of cytotoxic drugs. 
Table 9. Impact of the magnetosensitive 
nanocomposites Fe3O4/PAA and Fe3O4/γ-
APS carrying adsorbed cisplatin (CP) and the 
conjugated monoclonal antibody CD 95 on 
the vital activity of the MCF-7 line cells 
 
Fe3О4/ 
γ-APS 
+ CP 
Fe3О4/ 
γ-APS 
+ CD 95 
Fe3О4/ 
γ-АPS 
+ CP 
+ CD 95 
Fe3О4/ 
PАA 
+ CP 
Fe3О4/ 
PАА + 
CD 95 
Fe3О4/ 
PАА 
+ CP 
+ CD 95 
Suppres-
sed cells, 
% 
31 20 46 38 21 57 
 
      
 
CP, 
2,5 µg/ml 
CD 95, 
0,2 µg/ml 
CP, 2,5 µg/ml + 
CD 95, 0,2 µg/ml 
Suppres-
sed cells, 
% 
25 10 38 
 
Consequently, the impact of the 
magnetically driven nanocomposites (models of 
nanorobots) carrying the anti-tumour drug and 
the monoclonal antibody CD 95 on the cancer 
cells MCF-7 exerts a synergic effect and 
provides the desired cytotoxicity at lower 
concentrations. Thus the toxic effect of the 
medical chemotherapeutic preparation on a 
whole organism can be decreased. Magnetic 
properties of the nanorobot models, 
peculiarities of their transport in the vascular 
system, their use for creation of hyperthermia 
zones, desorption kinetics of the cytostatic drug 
and efficiency of its influence on cell lines are 
discussed elsewhere [3]. 
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CONCLUSIONS 
A method for preparation of magnetosensitive 
nanocomposites on basis of surface-modified 
magnetite carrying immobilized cisplatin and 
monoclonal antibody CD 95 (a medico-biological 
nanorobot model) was developed. 
Adsorption and covalent immobilization of 
monoclonal antibody CD 95 and human normal 
immunoglobulin on nanocomposites comprising 
magnetite coated with polyacrylamide and γ-
aminopropylsiloxane. Isotherms of covalent 
attachment of oxidized immunoglobulin via 
formation of Schiff bases and non-specific 
(physical) adsorption of the normal 
immunoglobulin were compared. Kinetics of 
release of the immunoglobulin to a model 
environment was studied. 
Interaction of the prepared models of 
nanorobots with the cell line MCF-7 was studied. 
It was shown that use of magnetically driven 
nanocomposites carrying the anti-tumour drug 
and the monoclonal antibody CD 95 causes a 
synergic cytotoxic effect which exceeds the 
influence of the control dozes up to 50%. 
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